UAB “Orkela”, legal entity code 304099538, registered address Jogailos g. 4, Vilnius, Republic of Lithuania (hereinafter – the Issuer), whose securities (hereinafter – the Bonds) are included and traded on the Nasdaq bond list, and which are also publicly offered under the base prospectus approved by the Bank of Lithuania on 14 November 2023 (hereinafter – the Prospectus), hereby informs of the following: The Issuer has concluded a EUR 40 million credit agreement with AB SEB Bank for the refinancing of Bond ...

Core Points - Sampo plc has initiated a share buyback program with a maximum value of EUR 200 million, which commenced on 7 August 2025 [1][2] - On 17 October 2025, Sampo plc acquired a total of 414,255 A shares at an average price of EUR 9.59 per share [1] - Following the transactions, Sampo plc now holds a total of 17,410,899 A shares, representing 0.65% of the total shares outstanding [2] Summary by Sections Share Buyback Program - The share buyback program was announced on 6 August 2025 and is in compliance with the Market Abuse Regulation (EU) 596/2014 [1] - The program is based on the authorization granted by Sampo's Annual General Meeting on 23 April 2025 [1] Transaction Details - The daily buyback volumes on 17 October 2025 were as follows: - AQEU: 5,272 shares at EUR 9.58 - CEUX: 136,961 shares at EUR 9.58 - TQEX: 44,905 shares at EUR 9.59 - XHEL: 227,117 shares at EUR 9.59 - The total buyback volume for the day was 414,255 shares at an average price of EUR 9.59 [1] Ownership Post-Transactions - After the disclosed transactions, Sampo plc's total ownership of A shares is 17,410,899, which constitutes 0.65% of the total shares [2]

Core Insights - Nextensa and Promobe have signed a nine-year fixed lease agreement for the entire Terraces office building in the Cloche d'Or district, indicating strong demand for office space in this area [1][2] - The lease rate is set at €40 per square meter per month, which is index-linked, reflecting a stable income stream for the developers [2] - The Terraces office building will offer 4,703 m² of lettable office space and is designed to achieve BREEAM Outstanding and WELL Gold certifications, showcasing a commitment to sustainability [3] Company Overview - Nextensa is a mixed-use real estate investor and developer focused on office, retail, and residential projects in Luxembourg, Belgium, and Austria [5] - Promobe is a significant player in real estate development within the Grand Duchy of Luxembourg, contributing to the growth of urban districts like Cloche d'Or [6] Project Details - The Terraces office building will consist of a ground floor and five upper levels, with construction expected to begin shortly and completion anticipated in Q2 2027 [2][3] - The Cloche d'Or district is rapidly developing, featuring over 120,000 m² of office space and excellent accessibility, including a tram line inaugurated in July 2024 [4]

Core Insights - Roche announced positive results from the phase III IMvigor011 study, showing that Tecentriq significantly improves overall survival and disease-free survival in muscle-invasive bladder cancer patients at risk of recurrence after surgery [1][3][6] Study Results - Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared to placebo [1][6] - At a median follow-up of 16.1 months, median disease-free survival (DFS) was 9.9 months for the Tecentriq group versus 4.8 months for the placebo group, with a stratified hazard ratio of 0.64 [3][4] - Median overall survival (OS) was 32.8 months for the Tecentriq group compared to 21.1 months for the placebo group, with a hazard ratio of 0.59 [3][4] Study Design - The IMvigor011 study was a global phase III, randomized, placebo-controlled, double-blind trial involving 761 participants, focusing on those with detectable circulating tumor DNA (ctDNA) [4] - The study utilized Natera's Signatera ctDNA test to guide treatment decisions, currently under FDA review as a companion diagnostic [4] Clinical Implications - The results indicate that ctDNA-guided treatment can help identify patients who would benefit from adjuvant therapy, potentially leading to more personalized treatment approaches [3][4] - More than 150,000 people are diagnosed with muscle-invasive bladder cancer annually, highlighting the need for effective treatment strategies [3]

Core Insights - Sanofi's high-dose influenza vaccine, Efluelda (Fluzone High-Dose in North America), shows significantly reduced hospitalization risk for adults aged 65 and older compared to standard-dose vaccines, as evidenced by the FLUNITY-HD study [1][4][3] Study Design and Results - The FLUNITY-HD study is the largest of its kind, involving nearly half a million participants across multiple seasons and geographic areas, demonstrating the effectiveness of the high-dose vaccine [4][6] - The study found a 31.9% additional reduction in laboratory-confirmed influenza hospitalizations for older adults receiving the high-dose vaccine compared to standard-dose [4][7] - Additional findings include an 8.8% reduction in pneumonia/influenza hospitalizations and a 6.3% reduction in hospitalizations due to cardio-respiratory events [4][7] Public Health Implications - The high-dose vaccine could prevent one all-cause hospitalization for every 515 older adults vaccinated, highlighting its potential to improve quality of life for vulnerable seniors and reduce healthcare costs [3][4] - The results may influence public health strategies and clinical guidelines, reinforcing the importance of high-dose vaccines for older adults [2][3] Product Information - Efluelda is specifically designed for adults aged 60 and older in Europe and for those aged 65 and older in North America, providing four times the antigen compared to standard-dose vaccines [8][9] - The vaccine aims to enhance immune response in older adults, who are at a higher risk for severe influenza-related illnesses [9]

Core Insights - FORVIA reported third-quarter 2025 sales of €6.12 billion, stable on an organic basis, but down 3.7% year-over-year due to negative currency effects [1][8][24] - The company confirmed its full-year 2025 guidance, maintaining targets for sales, operating margin, net cash flow, and leverage [3][25][29] Financial Performance - Consolidated sales in Q3 2025 were impacted by a €238 million negative currency effect, primarily from the euro's depreciation against the USD and RMB [8][24] - Organic growth in product sales was 1.1%, with solid growth in Electronics, Clean Mobility, and Lifecycle Solutions [7][10][11] - The company experienced a 440 basis points underperformance compared to global automotive production, which grew by 4.4% [8][15] Segment Analysis - **Seating**: Reported a decline of 12.7% in sales, affected by an unfavorable customer mix in China [9][11] - **Electronics**: Achieved a 14.3% increase in sales, driven by strong demand for radars and battery management systems [9][11] - **Interiors**: Experienced a slight decline in organic sales, primarily due to normalization of tooling sales [12] - **Clean Mobility**: Recorded strong growth, particularly in North America, benefiting from electrification trends [13] - **Lifecycle Solutions**: Returned to growth after five quarters of decline, driven by commercial vehicle business [13] Regional Performance - **EMEA**: Sales decreased by 2.5% on an organic basis, impacted by production shutdowns and market slowdowns [16][17] - **North America**: Organic sales advanced by 5.8%, driven by growth with US and Japanese car manufacturers [18] - **Asia**: Organic sales declined by 2.7%, with China down 7.4% due to an unfavorable customer mix [18][19] Strategic Initiatives - The company is focused on cost reduction and financial discipline through its EU-FORWARD initiative, which includes job reductions and a global SIMPLIFY program aimed at reducing costs by €110 million by 2028 [21][22] - FORVIA successfully raised approximately €1.3 billion in new financing to refinance short-term obligations and enhance its financial profile [23][24]

Core Insights - TGS has secured an OBN acquisition contract in the Gulf of America, with a 4D monitor survey set to begin in Q4 2025 and lasting approximately 4.5 months [1][2] Company Overview - TGS is a leading provider of energy data and intelligence, offering advanced technology and solutions across the entire energy value chain [3] - The company has a diverse energy data library and aims to support clients in making informed decisions regarding energy resource exploration and production [3] Market Position - The Gulf of America is identified as a core market for TGS's OBN business, highlighting the importance of this region for the company's operations [2] - The contract is with a repeat IOC customer, indicating a strong relationship and trust in TGS's capabilities [2]

Core Viewpoint - Roche's Gazyva®/Gazyvaro® (obinutuzumab) has received FDA approval for treating adult patients with active lupus nephritis, offering a new standard of care with a shorter infusion time and improved treatment regimen [1][2]. Group 1: FDA Approval and Treatment Efficacy - The FDA approved Gazyva/Gazyvaro for adult patients with active lupus nephritis who are on standard therapy, allowing for a 90-minute infusion after the first dose [1]. - In the phase III REGENCY study, 46.4% of participants receiving Gazyva/Gazyvaro achieved a complete renal response compared to 33.1% on standard therapy alone, indicating significant efficacy [2][8]. - The approval is based on positive results from both phase II NOBILITY and phase III REGENCY studies, demonstrating the drug's superiority over standard therapy [8]. Group 2: Patient Impact and Disease Background - Lupus nephritis affects over 1.7 million people globally, predominantly impacting women of color and those of childbearing age, with untreated cases leading to a one-third progression to end-stage kidney disease [3][11]. - The approval of Gazyva/Gazyvaro is seen as a significant advancement in providing hope for patients suffering from chronic pain and the fear of worsening kidney health [2][3]. Group 3: Future Prospects and Pipeline - Gazyva/Gazyvaro is also being investigated for other conditions, including systemic lupus erythematosus and various kidney-related diseases, indicating a broad pipeline for Roche in this therapeutic area [5][6]. - The European Medicines Agency has issued a positive opinion for Gazyva/Gazyvaro, with a final decision expected soon, suggesting potential for further market expansion [4].

Corbion hereby reports the transaction details related to its share buyback program announced on 1 September 2025. During the week of 13 October up to and including 17 October 2025 a total of 29.981 shares were repurchased at an average price of €16.6672 for a total amount of €499,698.04 To date, the total consideration for shares repurchased amounts to €5,024,854.16 representing 50.25% of the overall share buyback program. Corbion publishes on a weekly basis every Monday, an overview of the progress of the ...

Core Insights - The 3rd offline meeting of NexisPeak Global successfully concluded, focusing on themes of consensus, co-creation, and win-win strategies among investors and industry experts [2] - The conference emphasized innovative strategies and stable investments to achieve wealth growth and long-term value in the context of the global economic landscape and digital asset era [2] Company Strategies - NexisPeak Global's core cooperation team presented their latest strategic layout, including achievements like the SOR smart order system, agreement delivery mechanism, and annuity growth plan, marking advancements in intelligent trading and risk control systems [3] - The company advocates for a focus on insights over mere data in future investments, promoting multi-dimensional asset allocation and intelligent model decision-making to ensure steady growth in complex markets [5] Collaborative Efforts - Multiple partner representatives showcased their practical achievements, highlighting the effectiveness of team collaboration and strategic execution through real performance and growth experiences [6] - The meeting served as a platform for building trust and cooperation among partners, reinforcing the idea that growth is a collective effort [7] Future Vision - NexisPeak Global aims to continue its journey guided by a global vision, innovative technology, and robust strategies, working collaboratively with partners to establish a high-end ecosystem [7]